Brentuximab vedotin for the treatment of patients with hodgkin lymphoma

Hematology/Oncology Clinics of North America

Volumn 28, Issue 1, 2014, Pages 27-32

  Younes, Anas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody drug conjugate; CD30; Monoclonal antibody; Reed Sternberg

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BRENTUXIMAB VEDOTIN; DOXORUBICIN; GEMCITABINE; IRATUMUMAB; NAVELBINE; PLACEBO; SGN 30; UNCLASSIFIED DRUG; XMAB 2513;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ANTIBODY-DRUG CONJUGATE; CD30; MONOCLONAL ANTIBODY; REED-STERNBERG;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; NEOPLASM RECURRENCE, LOCAL; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84888788431     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.10.005     Document Type: Review

References (21)

1. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011, 23(6):587-593.
2. Younes A., Kadin M.E. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. JClin Oncol 2003, 21(18):3526-3534.
3. Durkop H., Latza U., Hummel M., et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992, 68(3):421-427.
4. Pizzolo G., Vinante F., Morosato L., et al. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994, 8(6):741-745.
5. Fattovich G., Vinante F., Giustina G., et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996, 103(1):105-110.
6. Giacomelli R., Cipriani P., Lattanzio R., et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997, 108(1):42-46.
7. Bartlett N.L., Younes A., Carabasi M.H., et al. Aphase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111(4):1848-1854.
8. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. JClin Oncol 2007, 25(19):2764-2769.
9. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011, 8(2):85-96.
10. Younes A., Yasothan U., Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012, 11(1):19-20.
11. Katz J., Janik J.E., Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011, 17(20):6428-6436.
12. Okeley N.M., Miyamoto J.B., Zhang X., et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010, 16(3):888-897.
13. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEngl J Med 2010, 363(19):1812-1821.
14. Fanale M.A., Forero-Torres A., Rosenblatt J.D., et al. Aphase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012, 18(1):248-255.
15. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. JClin Oncol 2012, 30(18):2183-2189.
16. Bartlett N.L., Niedzwiecki D., Johnson J.L., et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18(6):1071-1079.
17. Willems P.J. Dynamic mutations hit double figures. Nat Genet 1994, 8(3):213-215.
18. Marwick C. No obvious reason for HBV double hit. JAMA 1983, 250(1):20.
19. Campbell R. Childhood cancer: the 'double hit' disease. Nurs Mirror 1980, 151(9):ii-viii.
20. Schwab U., Stein H., Gerdes J., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299(5878):65-67.
21. Chen R.W., Gopal A.K., Smith S.E., et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). ASCO Meeting Abstracts 2011, 29(15 Suppl):8031.